Abdominoplasty, Medical Aesthetics
Conditions
Brief summary
Silk Medical Aesthetics' Inc. device, SMA-001, is currently under development as a dermal filler to fill wrinkles and folds. This study is designed to collect short-term visual, photographic, and histological and safety data on small aliquots of the product as part of device development. It is an open label study involving up to three investigational sites and a maximum enrollment of 10 subjects. Juvéderm Ultra Plus XC, an FDA-approved dermal filler will serve as a control device. Briefly, the investigational product and the control device will be injected into the abdomen of patients intending to undergo abdominoplasty at a later date. The patients will be followed for 30 days post injection through visual observation. At 30 days post injection, the injected gel and associated tissue will be removed via biopsy during the abdominoplasty surgery and histology slides created for analysis.
Interventions
DEVICESMA-001
Intra-dermal injection of SMA-001 and control device.
Sponsors
Silk Medical Aesthetics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
25 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Female, 25-65 years of age 2. Abdominoplasty patients with sufficient skin quality (dermal thickness & integrity, limited stretch marks/attenuated skin) 3. Able to follow study instructions and likely to complete all required visits, as assessed by the PI 4. Signed the IRB-approved Informed Consent form and the HIPAA form prior to performance of any study-related procedures
Exclusion criteria
1. Subjects with intrinsic skin disease or documented dermatologic conditions 2. Subjects with known bleeding disorders or on medications that may interfere with bleeding 3. Subjects currently taking immunosuppressive drugs, steroids, or anti-inflammatories 4. Subjects receiving injection of lipolytic drugs 5. Subjects with a history of keloid formation or hypertrophic scarring 6. Subjects with documented Type I or II Diabetes Mellitus. 7. Inability or unwillingness of the subject to complete the clinical protocol as described in the protocol and allow access to clinical records. 8. Subjects who are known to be pregnant at the time of enrollment or plan to become pregnant in the coming 30 days. 9. Subjects with documented active drug or alcohol abuse within the last 12 months prior to the study. 10. Subjects with systemic collagen disorders, such as Ehlers Danlos. 11. Subjects with known allergies to hyaluronic acid, silk, lidocaine, and/or Polyethylene Glycol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Histological performance | 4 weeks | Four week histology data |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 4 weeks | Safety of the device through Adverse Event tracking |
Countries
United States
Outcome results
None listed